Top Industry Leaders in the Rhabdomyosarcoma Market
Latest Rhabdomyosarcoma Companies Update
Pfizer Phase 2 trial evaluating PF-06945007 in combination with standard chemotherapy for recurrent rhabdomyosarcoma shows promising results, with higher progression-free survival rates compared to the control group.
Tarveda Therapeutics Phase 2 trial for ARV-111 demonstrates improved overall survival rates in patients with advanced rhabdomyosarcoma who have already received other treatments.
Boehringer Ingelheim International GmbH Phase 1/2 trial for BI 899554, a PARP inhibitor, reveals encouraging early activity in rhabdomyosarcoma patients, paving the way for further investigation.
List of Rhabdomyosarcoma Key Companies in the Market
- Boehringer Ingelheim International GmbH
- Pfizer Inc
- Eli Lilly & Company
- Novartis AG
- Bristol Myers Squibb Company
- TAIHO ONCOLOGY INC.
- Oasmia
- Bellicum Pharmaceuticals Inc.
- CELGENE CORPORATION
- Eisai Co. Ltd.
- MacroGenics Inc.
- Tarveda Therapeutics.
- Exelixis Inc.
- and Ipsen Pharma